Related Experiment Video
Updated: Jun 22, 2025
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma
Mahsa Palizkaran Yazdi1, Amirhosein Barjasteh2, Meysam Moghbeli3
1Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:
Glioblastoma (GBM) is an aggressive nervous system tumor with a poor prognosis. Although, surgery, radiation therapy, and chemotherapy are the current standard protocol for GBM patients, there is still a poor prognosis in these patients. Temozolomide (TMZ) as a first-line therapeutic agent in GBM can easily cross from the blood-brain barrier to inhibit tumor cell proliferation. However, there is a high rate of TMZ resistance in GBM patients. Since, there are limited therapeutic choices for GBM patients who develop TMZ resistance; it is required to clarify the molecular mechanisms of chemo resistance to introduce the novel therapeutic targets. MicroRNAs (miRNAs) regulate chemo resistance through regulation of drug metabolism, absorption, DNA repair, apoptosis, and cell cycle. In the present review we discussed the role of miRNAs in TMZ response of GBM cells. It has been reported that miRNAs mainly induced TMZ sensitivity by regulation of signaling pathways and autophagy in GBM cells. Therefore, miRNAs can be used as the reliable diagnostic/prognostic markers in GBM patients. They can also be used as the therapeutic targets to improve the TMZ response in GBM cells.
Insights
MicroRNAs (miRNAs) can overcome temozolomide (TMZ) resistance in glioblastoma (GBM) by regulating key cellular processes. These findings highlight miRNAs as potential diagnostic markers and therapeutic targets for improving GBM treatment outcomes.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with a poor prognosis despite standard treatments.
- Temozolomide (TMZ) is a first-line chemotherapy agent, but resistance significantly limits its efficacy.
- Understanding molecular mechanisms of chemoresistance is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To review the role of microRNAs (miRNAs) in modulating temozolomide (TMZ) response in glioblastoma (GBM).
- To explore miRNAs as potential diagnostic/prognostic markers and therapeutic targets for GBM patients with TMZ resistance.
Main Methods:
- Literature review focusing on the function of miRNAs in GBM chemoresistance.
- Analysis of miRNA-mediated regulation of drug metabolism, DNA repair, apoptosis, cell cycle, signaling pathways, and autophagy.
Main Results:
- MicroRNAs (miRNAs) play a significant role in regulating glioblastoma (GBM) cell sensitivity to temozolomide (TMZ).
- miRNAs primarily enhance TMZ sensitivity by modulating critical signaling pathways and autophagy.
- Dysregulation of specific miRNAs contributes to TMZ resistance in GBM.
Conclusions:
- MicroRNAs (miRNAs) are key regulators of temozolomide (TMZ) response in glioblastoma (GBM).
- miRNAs demonstrate potential as reliable diagnostic and prognostic biomarkers for GBM patients.
- Targeting miRNAs offers a promising therapeutic strategy to improve TMZ efficacy in GBM.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:22MicroRNAs